The companies will work with investigators to share the results with the scientific community
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
With this additional route of administration, the MMRV Family now joins other routinely recommended vaccines that can be administered intramuscularly
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
Merck intends to complete today the acquisition of Imago through a merger of Merck’s wholly owned subsidiary with and into Imago
Subscribe To Our Newsletter & Stay Updated
